ROCK2 and chronic graft versus host disease: Belumosudil, an inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2), was approved by the US Food and Drug Administration in 2021 for chronic graft-versus-host-disease (cGVHD) treatment [22], a disease with similar histopathological features as SSc.